U.S., Nov. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07939841) titled 'N-Acetylcysteine (NAC) in Primary Sclerosing Cholangitis (PSC)' on Nov. 10.

Brief Summary: Primary sclerosing cholangitis (PSC) is a chronic disease that causes inflammation and scarring of the bile ducts and can lead to progressive liver damage. There are currently no approved medications that have been shown to improve long-term outcomes in patients with PSC.

The purpose of this pilot study is to evaluate whether N-acetylcysteine (NAC), a medication that helps the body produce an antioxidant called glutathione, may improve liver blood tests in people with PSC.

This is a single-center, open-label study involving approximately 15 ...